Compare CRNX & STNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | STNG |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | Monaco |
| Employees | N/A | 24 |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.0B |
| IPO Year | 2018 | N/A |
| Metric | CRNX | STNG |
|---|---|---|
| Price | $36.66 | $80.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $76.75 | ★ $83.33 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.22% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | $4.31 |
| Revenue Next Year | $184.67 | N/A |
| P/E Ratio | ★ N/A | $10.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $37.96 |
| 52 Week High | $57.99 | $87.39 |
| Indicator | CRNX | STNG |
|---|---|---|
| Relative Strength Index (RSI) | 45.46 | 49.24 |
| Support Level | $33.19 | $80.14 |
| Resistance Level | $37.23 | $81.85 |
| Average True Range (ATR) | 2.17 | 2.96 |
| MACD | -0.18 | -0.68 |
| Stochastic Oscillator | 28.47 | 26.19 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.